Opus Genetics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Opus Genetics, Inc. (IRD) had Debt Securities, Available-for-sale, Amortized Cost of $14.97 million as of 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2018-05-04
- 2018-03-31: Debt Securities, Available-for-sale, Amortized Cost $14.97M.
- 2017-12-31: Debt Securities, Available-for-sale, Amortized Cost $17.99M.
- 2017-09-30: Debt Securities, Available-for-sale, Amortized Cost $14.99M.
- 2017-06-30: Debt Securities, Available-for-sale, Amortized Cost $18.01M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2018-03-31 | $14.97M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $17.99M 10-K · filed 2018-03-09 |
| 2017-09-30 | $14.99M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $18.01M 10-Q · filed 2017-08-04 |
| 2015-09-30 | $9.00M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $16.01M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $18.65M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $22.91M 10-K · filed 2015-03-16 |
| 2014-09-30 | $20.66M 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |